Baker BROS. Advisors LP increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 34.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,767,773 shares of the company's stock after acquiring an additional 969,057 shares during the period. Roivant Sciences comprises about 0.5% of Baker BROS. Advisors LP's holdings, making the stock its 26th largest holding. Baker BROS. Advisors LP owned approximately 0.52% of Roivant Sciences worth $44,573,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in shares of Roivant Sciences by 0.3% in the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after purchasing an additional 156,527 shares in the last quarter. Vanguard Group Inc. lifted its position in Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares in the last quarter. Two Seas Capital LP boosted its stake in shares of Roivant Sciences by 4.6% during the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after buying an additional 442,914 shares during the period. Invesco Ltd. grew its holdings in shares of Roivant Sciences by 49.7% during the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after acquiring an additional 3,159,603 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Roivant Sciences by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock worth $91,968,000 after acquiring an additional 26,727 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares in the company, valued at $12,197,277.80. This represents a 27.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,395,541 shares of company stock valued at $14,922,538. Company insiders own 7.90% of the company's stock.
Roivant Sciences Trading Up 1.0 %
NASDAQ ROIV traded up $0.11 during trading on Wednesday, hitting $11.17. 4,214,669 shares of the company traded hands, compared to its average volume of 5,540,412. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06. The business has a fifty day simple moving average of $10.46 and a 200 day simple moving average of $11.12. The company has a market capitalization of $7.97 billion, a P/E ratio of -74.46 and a beta of 1.23.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on ROIV shares. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.
Check Out Our Latest Stock Report on Roivant Sciences
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
